What is Glatiramer Acetate?

A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.

Glatiramer Acetate in the library · · Human Trials · What are peptides?

75 registered trials · 267 indexed papers · 267 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.

Type: Peptide polymer drug.

Definition (National Library of Medicine)

“A random polymer of l-alanine, l-glutamic acid, l-lysine, and l-tyrosine that structurally resembles myelin basic protein.”

  • MeSH: Glatiramer Acetate

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Glatiramer Acetate is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (75)

TrialPhaseStatusYearEnrolled
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral TherapyPhase 2not yet recruiting202636
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisPhase 3recruiting2026250
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosisrecruiting2022800
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babiesactive not recruiting20211178
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab [amount hidden] vs. First Line DMT in RMSPhase 3completed2021185
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabPhase 4terminated202124
Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart FailurePhase 2completed202114
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)Phase 2withdrawn2021
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).unknown2020130
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPhase 4active not recruiting2019800
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible TumorsPhase 1unknown201910
Czech Pharmaco-epidemiological Study on Disease Modifying Drugscompleted201917478
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trialcompleted2018900
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTPhase 3terminated201716
COMparison Between All immunoTherapies for Multiple Sclerosis.completed20173526
Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsPhase 2/Phase 3completed201784
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"completed20151332
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®Phase 4completed2015861
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Irancompleted2015368
An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett SyndromePhase 1unknown201410
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple SclerosisPhase 3completed2013158
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)Phase 2completed201310
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)Phase 2terminated2013255
Safety and Tolerability of Glatiramer AcetatePhase 3completed2013209
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxonePhase 3terminated20121064
Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetatePhase 2completed201253
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod [amount hidden] (EPOC)Phase 4completed2012298
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) [amount hidden] New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)Phase 3terminated2012178
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityPhase 2withdrawn2012
Efficacy and Safety of GTR in Comparison to Copaxone®Phase 3completed2011794
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangePhase 4completed201161
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection [amount hidden] Administered Three Times a Week Compared to PlaceboPhase 3completed20101404
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple SclerosisPhase 2withdrawn2010
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisPhase 3terminated201084
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) [amount hidden] vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisPhase 4completed20101053
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsPhase 3completed2010148
Treatment Interruption of NatalizumabPhase 2completed2010175
Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle ClosurePhase 3unknown2010196
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)Phase 3completed200944
Safety of New Formulation of Glatiramer AcetatePhase 3completed2009147

Peer-reviewed studies (267)

PaperAuthorsJournalYearType
Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the "GA transition" studySchiavetti I et al.Multiple sclerosis and related disorders2026Observational Study
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trialMiller A et al.Multiple sclerosis (Houndmills, Basingstoke, England)2026Randomized Controlled Trial
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisGavoille A et al.Journal of neurology, neurosurgery, and psychiatry2026Observational Study
A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple SclerosisSimone M et al.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025Randomized Controlled Trial
Real-World Comparison of High-Efficacy Versus Non-High-Efficacy Therapies in Multiple SclerosisAl-Araji S et al.Annals of clinical and translational neurology2025Observational Study
Safety and Effectiveness of Cinnomer(®) on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter StudyNaser Moghadasi A et al.Archives of Iranian medicine2023Clinical Trial, Phase IV
Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patientsSchreiber H et al.Neurodegenerative disease management2023Observational Study
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational studyMoreau A et al.Multiple sclerosis and related disorders2023Observational Study
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialDiouf I et al.Journal of neurology, neurosurgery, and psychiatry2023Randomized Controlled Trial
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE)Tuncer MA et al.Turkish journal of medical sciences2023Observational Study
Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational StudySieber C et al.JMIR mHealth and uHealth2022Observational Study
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyFord CC et al.Multiple sclerosis (Houndmills, Basingstoke, England)2022Randomized Controlled Trial
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSISLi J et al.Multiple sclerosis and related disorders2022Observational Study
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis LesionsZinger N et al.Neurology(R) neuroimmunology & neuroinflammation2022Observational Study
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosisKoch MW et al.European journal of neurology2022Randomized Controlled Trial
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple SclerosisKoch MW et al.Neurology2021Randomized Controlled Trial
Therapeutic inertia in relapsing-remitting multiple sclerosisRodrigues R et al.Multiple sclerosis and related disorders2021Observational Study
Modulation of Retinal Atrophy With Rituximab in Multiple SclerosisLambe J et al.Neurology2021Observational Study
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled TrialBellmann-Strobl J et al.Neurology(R) neuroimmunology & neuroinflammation2021Randomized Controlled Trial
B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple SclerosisTacke S et al.Neurology(R) neuroimmunology & neuroinflammation2021Clinical Trial
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS RegisterD'Amico E et al.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021Observational Study
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aBovis F et al.Neurology2021Randomized Controlled Trial
Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trialCheshmavar M et al.Acta neurologica Scandinavica2021Randomized Controlled Trial
The influence of glatiramer acetate on Th17-immune response in multiple sclerosisMelnikov M et al.PloS one2020Clinical Trial
Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity scoreLefort M et al.Pharmacoepidemiology and drug safety2020Observational Study
Comorbidity is associated with disease activity in MS: Findings from the CombiRx trialSalter A et al.Neurology2020Randomized Controlled Trial
Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, ItalyMarangi A et al.Multiple sclerosis and related disorders2020Observational Study
Satisfaction and adherence with glatiramer acetate [amount hidden] TIW in RRMS after 12 months, and the effect of switching from [amount hidden] QDCutter G et al.Multiple sclerosis and related disorders2020Randomized Controlled Trial
Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MSGranqvist M et al.Multiple sclerosis (Houndmills, Basingstoke, England)2020Observational Study
Effectiveness of dimethyl fumarate as first line therapy in MS patients - one center real life observation studySałacińska D et al.Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego2019Observational Study

More cited research

Conditions researched

Related compounds

FAQ

What is Glatiramer Acetate?

A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.

How many registered human trials study Glatiramer Acetate?

The PeptideWhiz trial index lists 75 registered trials for Glatiramer Acetate, the most recent from 2026.

How much published research exists on Glatiramer Acetate?

The PeptideWhiz paper index links 267 PubMed papers to Glatiramer Acetate; by study type, 267 human and 0 animal studies.

Which conditions is Glatiramer Acetate researched for?

Chronic and systemic inflammation, Cognition, focus & brain performance, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Eyes: macular degeneration & retinal health, Fatigue & low energy (incl. midlife), Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, Immune system (general), Multiple sclerosis, Osteoporosis and bone density, Pregnancy and breastfeeding: safety notes.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research